tirzepatide news october 18 2025 on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial FDA Grants Tirzepatide a New

Current guidelines support early use, especially for patients with cardiovascular risk or obesity

Although cases are very rare and there isnt enough data on this yet, these medications may be linked to an increased risk of gastroparesis

Accordingly, VSMC dysfunction ultimately aggravates vascular injury and accelerates the development of atherosclerosis

For weight management, NICE has approved semaglutide (Wegovy) for adults with specific BMI criteria (35 kg/m or 30 kg/m with weight-related comorbidities) within specialist weight management services

Research supports the idea that slow titration allows your body to adjust to the drug's effects, reducing the severity of side effects, including nausea

Our challenge as clinicians is to create systems and time to support people to initiate and stay on these effective treatments.